This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2 (I)

T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-f.sub.3-T.sub.4 (II), as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:
T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)
T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-f.sub.3-T.sub.4(II),
as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:
T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)
T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-f.sub.3-T.sub.4(II),
as described in the present application. Methods of using these macrostructures are also disclosed.

A kit for determining ctDNA concentration and a method for determining ctDNA concentration is disclosed, wherein the method comprising dissolving extracted ctDNA in Tris-HCl buffer with pH>7.0 and adding into the buffer 2,7-bis(1-methyl-4-vinylpyridine)-9-ethylcarbazole iodised salt as a molecular probe, calculating the concentration of ctDNA in the solution by measuring the Fluorescence intensity of the solution. It has extremely high sensitivity in the determination of 0 g/ml50 g/ml ctDNA solution.

A kit for determining ctDNA concentration and a method for determining ctDNA concentration is disclosed, wherein the method comprising dissolving extracted ctDNA in Tris-HCl buffer with pH>7.0 and adding into the buffer 2,7-bis(1-methyl-4-vinylpyridine)-9-ethylcarbazole iodised salt as a molecular probe, calculating the concentration of ctDNA in the solution by measuring the Fluorescence intensity of the solution. It has extremely high sensitivity in the determination of 0 g/ml50 g/ml ctDNA solution.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-C.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)

T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-f.sub.3-T.sub.4(II),

as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-C.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)

T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-f.sub.3-T.sub.4(II),

as described in the present application. Methods of using these macrostructures are also disclosed.

A dihydropyrimidinone derivative includes a compound having a chemical structure according to Formula 1: ##STR00001##
wherein Z is selected from CH.sub.2O, O, and N; X is selected from O and S; and R represents aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the substituted aryl or substituted heteroaryl have one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, hydroxyl, alkylthio, alkylamino, heteroaryl, aryloxy, haloaryloxy, arylthio, arylamino, and pharmaceutically acceptable salts thereof. The present subject matter also relates to a method of making a dihydropyrimidinone derivative, a method of treating a gastrointestinal disease, a method of treating an ulcer, a pharmaceutical composition, and a method of making a pharmaceutical composition.

A dihydropyrimidinone derivative includes a compound having a chemical structure according to Formula 1: ##STR00001##
wherein Z is selected from CH.sub.2O, O, and N; X is selected from O and S; and R represents aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the substituted aryl or substituted heteroaryl have one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, hydroxyl, alkylthio, alkylamino, heteroaryl, aryloxy, haloaryloxy, arylthio, arylamino, and pharmaceutically acceptable salts thereof. The present subject matter also relates to a method of making a dihydropyrimidinone derivative, a method of treating a gastrointestinal disease, a method of treating an ulcer, a pharmaceutical composition, and a method of making a pharmaceutical composition.